This review explores how genetic variants arise, their distribution across populations, and their involvement in monogenic, oligogenic and polygenic disorders and discusses the growing field of pharmacogenomics, which investigates how genetic differences affect drug metabolism, efficacy and toxicity.
Abstract
Human genetic variation plays a fundamental role in determining differences among individuals in disease susceptibility, clinical characteristics and responses to medical treatments. Advances in genomic technologies have significantly improved our ability to identify and characterize genetic differences, including single nucleotide variants, insertions and deletions, copy number variations and larger structural changes within the genome. These variations influence biological processes and contribute to both health and disease outcomes, making them essential to the development of precision medicine. This review examines the major forms of human genetic variation and their impact on disease development and pharmacological responses. It explores how genetic variants arise, their distribution across populations, and their involvement in monogenic, oligogenic and polygenic disorders. The review also highlights the importance of gene–environment interactions and epigenetic factors in shaping disease risk and progression. In addition, the paper discusses the growing field of pharmacogenomics, which investigates how genetic differences affect drug metabolism, efficacy and toxicity. Particular attention is given to clinically important variants in drug-metabolizing enzymes, transport proteins, and therapeutic targets that contribute to variability in treatment outcomes among patients. By linking disease genetics with pharmacogenomics, genetic information can be used both to predict disease risk and to guide individualized treatment strategies.
Peer Review History:
Received 5 April 2026; Reviewed 11 May 2026; Accepted 9 June; Available online 15 July 2026
Academic Editor: Dr. Muhammad Zahid Iqbal, AIMST University, Malaysia, drmmziqbal@gmail.com
Reviewers:
Dr. Hasniza Zaman Huri, University of Malaya Medical Centre, Kuala Lumpur, hasnizazh@ummc.edu.my
Dr. Hayriye Eda Şatana Kara, Gazi University, Turkey, eda@gazi.edu.tr
This review sequentially examines the main factors, classical and modern models of complex pathological phenotypes, as well as the achievements and prospects of analyzing inherited genetic variants in relation to CDs, and proposes an integrative hypothesis postulating that inherited genetic variants form a body-wide pr...
M. Nazarenko, A. Sleptcov, V. P. Puzyrev· Vavilovskii zhurnal genetiki...· 0 citations
The available evidence suggests that genetic aging is caused by a still-interacting series of processes, among which are genomic instability, telomere shortening, DNA damage accumulation, DNA damage accumulation, epigenomic dysregulation, mitochondrial dysfunction and changes in nutrient-sensing pathways.
G. M. Khalaf· Journal of Al-Turath Univers...· 0 citations
Type 2 Diabetes (T2D) is a complex disease that has increased in prevalence in the last years affecting over 530 million people around the world. T2D increases mortality and morbidity by different mechanisms. As a complex disease, it is caused by many genetic changes and, consequently, T2D genetics has been analyzed fr...
Celeste Moya-Valera, Mariana de Jesús Gallardo Espinoza, Alexander Arita et al.· Molecular Metabolism· 0 citations
Pharmacogenomics (PGx) is a key component of precision medicine, linking genetic variation to drug response, effectiveness, and toxicity. However, Middle Eastern and North African (MENA) populations remain underrepresented in global genomic databases, limiting PGx’s clinical utility in these regions. This review examin...
Abderraouf Haitamar, Shahid Eiyad Abu-Nada, Mariam Wed Eladham et al.· Frontiers in Pharmacology· 0 citations
Recent developments have expanded the understanding of the way the genetic basis of autism manifests phenotypically, and illustrate the therapeutic potential of gene-first approaches for selected monogenic neurodevelopmental disorders.
V. Eapen, A. Stylianakis, I. Voineagu· Current Opinion in Psychiatr...· 0 citations
The reasons for the slow pace of the diffusion of polygenic risk scores, along with the related field of pharmacogenomics, may be useful in clinical practice for the prevention and treatment of common diseases are reviewed.
David J. Hunter, Michael Inouye· New England Journal of Medic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.